Fig. 2From: FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma68 year old man with imaging for advanced cutaneous squamous cell carcinoma involving the right skull base, right infratemporal fossa and right trigeminal nerve managed with cemiplimab 350 mg/3-weekly. a demonstrating avid disease at baseline and (b) a CMR post 24 cycles. c demonstrating 41 × 23 mm enhancing mass on baseline MRI and (d) an ongoing RECIST1.1 PR post 24 cyclesBack to article page